Cargando…
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies
BACKGROUND: IDH-wildtype glioblastoma (GBM) is a highly malignant primary brain tumor with a median survival of 15 months after standard of care, which highlights the need for improved therapy. Personalized combination therapy has shown to be successful in many other tumor types and could be benefic...
Autores principales: | Houweling, Megan, Giczewska, Anna, Abdul, Kulsoom, Nieuwenhuis, Ninke, Küçükosmanoglu, Asli, Pastuszak, Krzysztof, Buijsman, Rogier C, Wesseling, Pieter, Wedekind, Laurine, Noske, David, Supernat, Anna, Bailey, David, Watts, Colin, Wurdinger, Thomas, Westerman, Bart A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347974/ https://www.ncbi.nlm.nih.gov/pubmed/37455945 http://dx.doi.org/10.1093/noajnl/vdad073 |
Ejemplares similares
-
Longitudinal drug synergy assessment using convolutional neural network image-decoding of glioblastoma single-spheroid cultures
por: Giczewska, Anna, et al.
Publicado: (2023) -
Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma
por: Brahm, Cyrillo G, et al.
Publicado: (2020) -
MEK/MELK inhibition and blood–brain barrier deficiencies in atypical teratoid/rhabdoid tumors
por: Meel, Michaël H, et al.
Publicado: (2020) -
Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023) -
Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss
por: Kaur, K, et al.
Publicado: (2009)